Alpha Lipoic Acid

Alpha-lipoic acid (ALA, also called thioctic acid) is a sulfur-containing compound studied across diabetic peripheral neuropathy (its primary clinical application), inflammatory and antioxidant biomarkers, metabolic syndrome markers including glucose tolerance and lipid profiles, weight management, cognitive function, and several smaller research areas. The compound is synthesized in the mitochondria and obtained from dietary sources; it functions as both a fat-soluble and water-soluble antioxidant and is one of the few compounds that can regenerate other antioxidants (vitamin C, vitamin E, glutathione). The R-enantiomer is the biologically active form, though most consumer products contain a racemic R/S mixture.

The outcome dimensions covered most heavily are diabetic peripheral neuropathy (where ALA has been used in European clinical practice for decades, with extensive trial and meta-analytic coverage), inflammatory biomarkers including high-sensitivity C-reactive protein and oxidative stress markers, metabolic syndrome markers including fasting glucose and lipid profiles, weight management (smaller and more contested literature), and antioxidant effects in various clinical contexts. Newer research streams cover cognitive function in mild cognitive impairment, mitochondrial-disease contexts, and chemotherapy-induced peripheral neuropathy.

Demographically, the diabetic neuropathy literature concentrates on adults with type 2 diabetes and documented neuropathy; the metabolic-marker literature is broader across adults with metabolic risk factors. Form variability is a methodological complication: R-only ALA, racemic R/S-ALA, and sodium-R-lipoate (a more stable form) are not interchangeable across the literature, and bioavailability differences are well-documented. European clinical practice typically uses higher doses than US consumer supplementation, which is one of the differences between clinical-application and consumer-context research.

ALA is generally well-tolerated at typical supplemental doses (200-600 mg/day) and at the higher clinical doses used for diabetic neuropathy (up to 1,800 mg/day in some trials). The most-common adverse effects are gastrointestinal (nausea, vomiting), occasional skin rash, and (rarely) symptomatic hypoglycemia in people with diabetes because ALA affects glucose metabolism. A rare but documented adverse event is autoimmune insulin syndrome (Hirata disease), reported most often in Japan, with a growing share of European cases, and associated with certain HLA genetic markers that are not identifiable without genetic testing. Drug interactions include theoretical additive hypoglycemia with diabetes medications (requires monitoring), possible interference with thyroid hormone therapy (animal data on T4-to-T3 conversion), and possible interactions with chemotherapy agents (a debated topic in oncology). People with diabetes on insulin or oral hypoglycemics should consult a clinician before starting; those on levothyroxine should ask a clinician.

This summary is informational and not medical advice. Consult a clinician before starting or changing any supplement, especially if you take prescription medications.